CHEMOCENTRYX INC (CCXI) 51.99 +0.03 (+0.06%)
51.99 +0.03 (+0.06%)
US16383L1061 - Common Stock - After market: 51.99 0 (0%)
Fundamental Rating
We assign a fundamental rating of 4 out of 10 to CCXI. CCXI was compared to 641 industry peers in the Biotechnology industry. CCXI scores bad on very profitability, while its financial health is fine. Not spectacular, but in line with the averages. CCXI is valued quite expensive, but it does show an excellent growth.
Profitability
Profitability Rating
The profitability ratios for CCXI are negative, so there is not much use analyzing them.
CCXI's Return On Assets of -31.74% is worse than the rest of the industry. The industry average Return On Assets is 12.39%. 100% of the industry peers have a better Return On Assets.
CCXI has a Profit Margin of -357.01%. This is below the industry average of 27.64%. 100% of the industry peers outperform CCXI.
CCXI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of CCXI.
VS Industry
ROA (-31.74%) VS Industry: 0% outperformed.
0.11
52.28
Profit Margin (-357.01%) VS Industry: 0% outperformed.
0.84
1,971.30
Valuation
Valuation Rating
The Price/Earnings Ratio is negative for CCXI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CCXI. No positive earnings are expected for the next year.
When comparing the current price to the book value of CCXI, we can conclude it is valued rather expensively. It is trading at 15.68 times its book value.
Compared to an average industry price book ratio of 1.89, CCXI is valued more expensive than its industry peers. 96% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Book (15.68) VS Industry: 4% outperformed.
448.49
0.07
Growth
Growth Rating
CCXI is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 47.34% yearly.
CCXI shows a strong growth in Revenue. In the last year, the Revenue has grown by 72.49%.
Measured over the past 5 years, CCXI shows a very strong growth in Revenue. The Revenue has been growing by 21.96% on average per year.
CCXI is expected to show a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 134.59% yearly.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
The earnings per share for CCXI have decreased by -6.78% in the last year.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -6.78% | 9.69% | 37.13% | 41.06% | 47.34% |
| Revenue | 21.96% | -9.08% | 72.49% | 117.77% | 157.52% | 130.02% | 134.59% |
Health
Health Rating
CCXI has a Current Ratio of 4.54. This indicates that CCXI is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 4.47 indicates that CCXI has no problem at all paying its short term obligations.
CCXI has an Altman-Z score of 9.70. This indicates that CCXI is financially healthy and little risk of bankruptcy at the moment.
The Altman-Z score of CCXI is much better than the industry average of -0.10. CCXI has a better rating than 85% of its industry peers.
When comparing the Debt to Equity Ratio of CCXI to the average industry Debt to Equity Ratio of 0.00, CCXI required more debt to finance its operations than its industry peers.
We won't put much weight on the industry comparison as CCXI has a very low Debt to Equity (0.02).
We won't put much weight on the industry comparison as CCXI has a very low Debt to Equity (0.02).
When comparing the Current Ratio of CCXI to the average industry Current Ratio of 6.18, CCXI is less able to pay its short term obligations than its industry peers.
When comparing the Quick Ratio of CCXI to the average industry Current Ratio of 6.05, CCXI is less able to pay its short term obligations than its industry peers.
The Piotroski-F score of CCXI is 3.00. This is a low score and indicates issues in the health and profitability of CCXI.
VS Industry
Debt/Equity (0.02) VS Industry: 33% outperformed.
15.37
0.00
Quick Ratio (4.47) VS Industry: 37% outperformed.
0.04
84.53
Current Ratio (4.54) VS Industry: 37% outperformed.
0.08
85.09
Altman-Z (9.7) VS Industry: 85% outperformed.
-2,801.75
658.20
Dividend
Dividend Rating
No dividends for CCXI!.
CHEMOCENTRYX INC51.99
NASDAQ:CCXI (10/19/2022, 7:04:24 PM)+0.03 (+0.06%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 08-08 2022-08-08/amc | Earnings (Next) | 11-08 2022-11-08/amc |
| Inst Owners | 78.02% | Inst Owner Change | -5.07% |
| Ins Owners | 0.1% | Ins Owner Change | -4185.44% |
| Market Cap | 3.71B | Analysts | 52.31 |
| Price Target | 53.04 (2.02%) | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Dividend Growth(5Y) | N/A | DP | N/A |
| Div Incr Years | N/A | Div Non Decr Years | N/A |
| Ex-Date | N/A | ||
| EPS beat(2) | 1 | Avg EPS beat(2) | -30.65% |
| Min EPS beat(2) | -73.94% | Max EPS beat(2) | 12.63% |
| EPS beat(4) | 3 | Avg EPS beat(4) | -7.25% |
| Min EPS beat(4) | -73.94% | Max EPS beat(4) | 29.7% |
| Revenue beat(2) | N/A | Avg Revenue beat(2) | -41.92% |
| Min Revenue beat(2) | -74.96% | Max Revenue beat(2) | -8.87% |
| Revenue beat(4) | 1 | Avg Revenue beat(4) | -25.25% |
| Min Revenue beat(4) | -74.96% | Max Revenue beat(4) | 29.07% |
| PT rev (1m) | N/A | PT rev (3m) | N/A |
| EPS NQ rev (1m) | N/A | EPS NQ rev (3m) | N/A |
| EPS NY rev (1m) | N/A | EPS NY rev (3m) | N/A |
| Revenue NQ rev (1m) | N/A | Revenue NQ rev (3m) | N/A |
| Revenue NY rev (1m) | N/A | Revenue NY rev (3m) | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 99.51 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 15.68 | ||
| P/tB | 15.68 | ||
| EV/EBITDA | -26.68 |
| EPS(TTM) | -1.89 | EY | N/A |
| EPS(NY) | -0.23 | Fwd EY | N/A |
| FCF(TTM) | -0.83 | FCFY | N/A |
| OCF(TTM) | -0.75 | OCFY | N/A |
| SpS | 0.52 | BVpS | 3.31 |
| TBVpS | 3.32 | PEG (NY) | N/A |
| PEG (5Y) | N/A | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.74% | ||
| ROE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -353.17% | ||
| PM | -357.01% | ||
| GM | N/A |
| ROICexgc(3y) | N/A | ROICexcg growth 3Y | N/A |
| ROICexcg growth 5Y | N/A | ROICexc(3y) | N/A |
| ROICexc growth 3Y | N/A | ROICexc growth 5Y | N/A |
| OM growth 3Y | N/A | OM growth 5Y | N/A |
| PM growth 3Y | N/A | PM growth 5Y | N/A |
| GM growth 3Y | N/A | GM growth 5Y | N/A |
| F-Score | 3 | Asset Turnover | 0.09 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 134.75% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.54 | ||
| Quick Ratio | 4.47 | ||
| Altman-Z | 9.7 |
| F-Score | 3 | WACC | 9.62% |
| ROIC/WACC | N/A | Cap/Depr(3y) | 860.12% |
| Cap/Depr(5y) | 583.3% | Profit Quality(3y) | N/A |
| Profit Quality(5y) | N/A | ||
| EPS 1Y | -6.78% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 21.43% |
| EPS Next Y | 9.69% | EPS Next 2Y | 37.13% |
| EPS Next 3Y | 41.06% | EPS Next 5Y | 47.34% |
| Revenue growth 1Y | 72.49% | Revenue growth 3Y | -9.08% |
| Revenue growth 5Y | 21.96% | Revenue growth Q2Q | 548.81% |
| Revenue Next Year | 117.77% | Revenue Next 2Y | 157.52% |
| Revenue Next 3Y | 130.02% | Revenue Next 5Y | 134.59% |
| EBIT growth 1Y | N/A | EBIT growth 3Y | N/A |
| EBIT growth 5Y | N/A | EBIT Next Year | N/A |
| EBIT Next 3Y | N/A | EBIT Next 5Y | N/A |
| FCF growth 1Y | 30.95% | FCF growth 3Y | N/A |
| FCF growth 5Y | N/A | OCF growth 1Y | 35.33% |
| OCF growth 3Y | N/A | OCF growth 5Y | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA